Development, licensing and supply of pharmaceutical products worldwide.
Galenicum Axium is the new name for our well-established business-to-business operations within the Galenicum ecosystem, taking us one step closer to becoming a global specialty pharmaceutical company.
Under this new brand, our team will continue to strengthen our position in the Active Pharmaceutical Ingredients (API) field, as well as in Research and Development, Licensing and the Supply of high-quality affordable Finished Dosage Forms (FDFs) to other pharmaceutical companies around the globe.
We are grateful for the commercial relationships that we currently have in place, which extend to over two hundred pharmaceutical companies in forty countries around the world. We are ready and keen to develop more!
The new brand name ‘Galenicum Axium’ encompasses three main elements, or ‘axes’: ‘science’, ‘connection’ and ‘challenge’. These three pivotal axes truly reflect our value proposition and our attitude as a company.
‘Science’ is our ‘x-axis’, as it is the core element of our work within the pharmaceutical industry. At Galenicum Axium, we devote a significant amount of resources and energy to research and development (R&D) activities, with the aim of continually expanding and improving our product portfolio to the benefit of our clients and their patients.
Our Intellectual Property, R&D, Clinical and Regulatory teams do not only have significant technical expertise and know-how but also the superb interpersonal and creative skills needed to address any project. This is in part why our clients come back to us time and time again.
We develop, license and supply pharmaceutical products worldwide covering most therapeutic areas.
Trading of Active Pharmaceutical Ingredients from leading manufacturers in a wide range of categories.